| Literature DB >> 32284902 |
Michael P Catalino1, Virginia Pate2, Til Stürmer2, Deb A Bhowmick1.
Abstract
INTRODUCTION: In older patients with axis fractures, the survival benefit from surgery is unclear due to high baseline mortality. Comparative effectiveness research can provide evidence from population level cohorts. Propensity weighting is the preferred methodology for reducing bias when analyzing national administrative cohort data for these purposes but has not yet been utilized for this important surgical conundrum. We estimate the effect of surgery on mortality after isolated acute traumatic axis fracture in older adults.Entities:
Keywords: Medicare; axis fracture; mortality; propensity methods; surgery
Year: 2020 PMID: 32284902 PMCID: PMC7133078 DOI: 10.1177/2151459320911867
Source DB: PubMed Journal: Geriatr Orthop Surg Rehabil ISSN: 2151-4585
Baseline Characteristics by Treatment for Isolated Axis Fractures only for Patients With at Least 1-Year Follow-Up Available Treated Operatively or Nonoperatively.a
| Characteristic | Surgery, N = 223 | No Surgery, N = 2097 | Unweighted | No Surgery | Weighted |
|---|---|---|---|---|---|
| Age group | |||||
| 65-74 | 52 (23.3%) | 356 (17.0%) | 0.159 | 61 (27.3%) | 0.091 |
| 75-84 | 107 (48.0%) | 747 (35.6%) | 0.253 | 92 (41.0%) | 0.141 |
| 85+ | 64 (28.7%) | 994 (47.4%) | 0.393 | 71 (31.7%) | 0.066 |
| Age, mean (SD) | 80.1 (7.19) | 83.0 (7.91) | 0.385 | 80.0 (7.79) | 0.013 |
| Sex, male | 75 (33.6%) | 613 (29.2%) | 0.095 | 77 (34.6%) | 0.020 |
| Race, nonwhite | 12 (5.4%) | 173 (8.2%) | 0.114 | 12 (5.4%) | 0.001 |
| Region | |||||
| Northeast | 29 (13.0%) | 435 (20.7%) | 0.208 | 28 (12.5%) | 0.014 |
| Midwest | 67 (30.0%) | 562 (26.8%) | 0.072 | 67 (30.1%) | 0.002 |
| South | 87 (39.0%) | 803 (38.3%) | 0.015 | 88 (39.5%) | 0.010 |
| West | 40 (17.9%) | 297 (14.2%) | 0.103 | 40 (17.8%) | 0.002 |
| Charlson comorbidity index, mean (SD) | 3.3 (2.58) | 3.7 (2.69) | 0.141 | 3.3 (2.60) | 0.011 |
| Frailty score, mean (SD) | 0.3 (0.26) | 0.4 (0.30) | 0.407 | 0.3 (0.26) | 0.003 |
| Mechanism | |||||
| High energy | 22 (9.9%) | 276 (13.2%) | 0.103 | 22 (10.0%) | 0.005 |
| Low energy | 179 (80.3%) | 1645 (78.4%) | 0.045 | 180 (80.2%) | 0.001 |
| No E code | 22 (9.9%) | 176 (8.4%) | 0.051 | 22 (9.8%) | 0.004 |
| Baseline outpatient office visits | |||||
| 0-6 | 75 (33.6%) | 848 (40.4%) | 0.141 | 75 (33.4%) | 0.006 |
| 7-12 | 73 (32.7%) | 572 (27.3%) | 0.119 | 73 (32.6%) | 0.002 |
| 13+ | 75 (33.6%) | 677 (32.3%) | 0.029 | 76 (34.0%) | 0.008 |
| Baseline home health claims | |||||
| 0 | 176 (78.9%) | 1485 (70.8%) | 0.188 | 177 (78.9%) | 0.001 |
| 1 | 25 (11.2%) | 311 (14.8%) | 0.108 | 25 (11.1%) | 0.003 |
| 2+ | 22 (9.9%) | 301 (14.4%) | 0.138 | 22 (10.0%) | 0.005 |
| Days in hospital during baseline | |||||
| <1 week | 174 (78.0%) | 1564 (74.6%) | 0.081 | 175 (78.0%) | 0.001 |
| 1 to <2 weeks | 19 (8.5%) | 285 (13.6%) | 0.162 | 19 (8.5%) | 0.002 |
| 2+ weeks | 30 (13.5%) | 248 (11.8%) | 0.049 | 30 (13.5%) | 0.003 |
| Any SNF stay during baseline | 27 (12.1%) | 387 (18.5%) | 0.177 | 27 (11.9%) | 0.006 |
| Baseline DME claims | |||||
| 0 | 109 (48.9%) | 1088 (51.9%) | 0.060 | 110 (49.1%) | 0.004 |
| 1 | 39 (17.5%) | 263 (12.5%) | 0.139 | 39 (17.4%) | 0.003 |
| 2+ | 75 (33.6%) | 746 (35.6%) | 0.041 | 75 (33.6%) | 0.001 |
| Baseline ED visits | |||||
| 0-1 | 104 (46.6%) | 769 (36.7%) | 0.203 | 105 (46.9%) | 0.005 |
| 2-5 | 104 (46.6%) | 1124 (53.6%) | 0.140 | 104 (46.3%) | 0.007 |
| 6+ | 15 (6.7%) | 204 (9.7%) | 0.109 | 15 (6.8%) | 0.003 |
| Distinct generic drugs at baseline | |||||
| 0-4 | 26 (11.7%) | 239 (11.4%) | 0.008 | 26 (11.5%) | 0.006 |
| 5-9 | 74 (33.2%) | 576 (27.5%) | 0.125 | 75 (33.7%) | 0.011 |
| 10+ | 123 (55.2%) | 1282 (61.1%) | 0.121 | 123 (54.8%) | 0.007 |
| ACE inhibitors | 83 (37.2%) | 740 (35.3%) | 0.040 | 83 (37.2%) | 0.000 |
| Antiarrhytmics | 30 (13.5%) | 237 (11.3%) | 0.065 | 30 (13.3%) | 0.003 |
| Anticoagulants | 70 (31.4%) | 737 (35.1%) | 0.080 | 70 (31.3%) | 0.003 |
| β-Blockers | 111 (49.8%) | 1094 (52.2%) | 0.048 | 112 (50.0%) | 0.005 |
| Bisphosphonates | 36 (16.1%) | 351 (16.7%) | 0.016 | 35 (15.6%) | 0.014 |
| Calcium-channel blockers | 61 (27.4%) | 675 (32.2%) | 0.106 | 60 (27.0%) | 0.009 |
| Loop diuretics | 57 (25.6%) | 736 (35.1%) | 0.209 | 56 (25.2%) | 0.008 |
| NSAIDs | 61 (27.4%) | 457 (21.8%) | 0.129 | 61 (27.2%) | 0.002 |
| PPI | 76 (34.1%) | 776 (37.0%) | 0.061 | 76 (33.9%) | 0.003 |
| Statin | 106 (47.5%) | 950 (45.3%) | 0.045 | 106 (47.5%) | 0.001 |
| Thiazides | 50 (22.4%) | 400 (19.1%) | 0.083 | 49 (22.0%) | 0.010 |
Abbreviations: ACE, acetylcholinesterase; DME, durable medical equipment; ED, emergency department; NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor; SD, standard deviation; Std Diff, standardized absolute mean difference; SNF, skilled nursing facility.
a Weighted standardized differences for nonsurgical cohort included for nonsurgical group.
Figure 1.Flow chart for determination of isolated acute axis fractures.
Figure 2.Bar and line graphs for age stratified fracture incidence and rate of surgical intervention during study period showing increasing incidence with age and stable rate of surgery.
Crude Mortality Rate Presented as Deaths Per 100 Patients.a
| Group | Inhospital | 30 Days | 180 Days | 360 Days |
|---|---|---|---|---|
| No surgery | 5.8 (4.9-6.7) | 13.3 (12.0-14.6) | 25.7 (23.9-27.4) | 33.9 (31.8-35.9) |
| Surgery | 3.6 (1.4-5.8) | 6.3 (3.4-9.1) | 15.1 (10.7-19.6) | 19.7 (14.5-25.0) |
a 95% Confidence intervals.
Figure 3.Bar and line graphs showing 1-year mortality in patients with isolated acute traumatic axis fractures stratified by age as well as propensity-weighted risk difference comparing mortality in surgical patients with nonsurgical patients. Poisson regression was used to estimate the rates and risk differences. It shows 95% confidence intervals and significantly decreased mortality in the 65 to 74 age-group.